NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Artiva Biotherapeutics, Inc. (ARTV) Stock Analysis

Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ARTV

$6.49

−$0.07 (−1.07%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARTV with… →

ARTV Key Statistics

As of Oct 21, 2026
Trading
Open
$6.60
Previous Close
$6.56
Day's Range
6.44–6.74
52-Week Range
2.96–14.53
Volume
363.66K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.41
Valuation
Market Cap
$317.30M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.23
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$83.87M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.89M
1-Year Return
+48.85%
Dividend and dates
Avg Volume
408.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ARTV closed at $6.49, +48.85% over 1 year.

Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $317.30M.

In fiscal 2025, ARTV reported revenue of $0.00.

ARTV Stock Return by Calendar Year

Artiva Biotherapeutics, Inc. (ARTV) return since Jul 2024: what $10,000 became

1 year
$10,000 $14,885
+48.85%
Since Jul 2024
$10,000 $5,408
−45.92%

If you had invested $10,000 in Artiva Biotherapeutics, Inc. (ARTV) at the close on July 19, 2024, the earliest close on record here, it would have been worth $5,408 at the close on October 21, 2026: −45.92% in total, −23.85% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+51.28%
2025−57.44%
2024 (partial year)−16.00%

As of October 21, 2026.

ARTV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$83.87M—
2024$251.00K−$58.18M−23,178.9%
2023$33.49M−$32.77M−97.8%
2022$4.93M−$60.98M−1,236.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$89.81M−$83.87M—
2024$251.00K—−$67.28M−$58.18M−23,178.9%
2023$33.49M—−$30.67M−$32.77M−97.8%
2022$4.93M—−$59.83M−$60.98M−1,236.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Artiva Biotherapeutics, Inc. (ARTV) is capitalised at $317.30M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 115.

ARTV last closed at $6.49 on October 21, 2026. That is −$0.07 (−1.07%) against the previous close. The 52-week range on file runs from $2.96 to $14.53. The latest close sits 119.26% above that 52-week low.

Financial Health

In fiscal 2025, Artiva Biotherapeutics, Inc. reported revenue of $0.00. Against the prior fiscal year total of $251.00K, that is a change of −100.00%. The same year closed with a net loss of $83.87M. Trailing earnings per share are −3.23.

Across the 4 fiscal years on file, revenue moves from $4.93M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +48.85%. The stored price history starts on July 19, 2024, and the total return since then is −45.92%. Beta against the wider market is reported at 2.41. Annualized volatility over the trailing 2 years is 154.64%.

Growth & Income

No dividend is on file for ARTV.

So far in 2026 the total return is +51.28%. The record holds one complete calendar year, 2025, which returned −57.44%.

Peer Comparison

Artiva Biotherapeutics, Inc. (ARTV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Artiva Biotherapeutics, Inc. ARTV $317.30M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Artiva Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Visit website →